(Q36921672)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

The importance of free fatty acids in the development of Type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Wilding JP

series ordinal

1

1 reference

17 August 2017

language of work or name

1 reference

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

934-945

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Duration of Obesity Increases the Incidence of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Screening for impaired glucose tolerance. Results from a population-based study in 21,057 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Diabetes incidence in an Australian aboriginal population. An 8-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Obesity and body fat distribution in relation to the incidence of non-insulin-dependent diabetes mellitus. A prospective cohort study of men in the normative aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

The relationship between body mass index and the prevalence of obesity-related diseases based on the 1995 National Health Interview Survey in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Differential effects of BMI on diabetes risk among black and white Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Splanchnic lipolysis in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effects of weight loss on regional fat distribution and insulin sensitivity in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Seven-year changes in body fat and visceral adipose tissue in women. Association with indexes of plasma glucose-insulin homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Metabolism of adipose tissue in intraabdominal depots of nonobese men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Differences at the Receptor and Postreceptor Levels Between Human Omental and Subcutaneous Adipose Tissue in the Action of Insulin on Lipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Relationship between visceral fat accumulation and anti-lipolytic action of insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Abdominal fat distribution and metabolic risk factors: effects of race.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Dose-response effect of elevated plasma free fatty acid on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Inhibition of insulin gene expression by long-term exposure of pancreatic beta cells to palmitate is dependent on the presence of a stimulatory glucose concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Changes in risk factors for cardiovascular disease with body fat loss in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Association of physical activity and serum insulin concentrations in two populations at high risk for type 2 diabetes but differing by BMI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

A population perspective on diabetes prevention: whom should we target for preventing weight gain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Prevention of diabetes: lifestyle and metformin are the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2007.02186.X

10.1111/J.1464-5491.2007.02186.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17725706%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference